InMode Rejects Three Acquisition Bids Valued Up to 1.1 Billion Dollars to Halt Company Sale

InMode stock falls 6.5% as the medical tech firm ends its sale process. Learn why the board rejected a $1.1 billion valuation from international investors.

By: AXL Media

Published: Feb 24, 2026, 5:19 AM EST

Source: The information in this article was sourced from Calcalist.

InMode Rejects Three Acquisition Bids Valued Up to 1.1 Billion Dollars to Halt Company Sale - article image
InMode Rejects Three Acquisition Bids Valued Up to 1.1 Billion Dollars to Halt Company Sale - article image

The Abrupt Termination of Global Sale Negotiations

The board of directors at InMode has officially ceased the exploration of a potential sale, concluding a period of strategic review that saw several high-profile offers. According to Golan Hazani, an independent committee tasked with evaluating these bids determined that none of the submitted proposals met the criteria for a successful exit. The rejection involves three distinct groups, including a bid for a majority stake and a competing offer from a consortium that featured the company’s own executive leadership. This cessation of talks represents a significant strategic pivot for the medical technology firm, which has seen its valuation fluctuate amid these negotiations.

Competitive Interests from Korean and American Investment Groups

The competitive landscape for medical aesthetics equipment is currently shaped by high interest rates and cautious private equity activity, which likely influenced the bidding terms. According to industry reports, the offers came from a diverse range of international players, including the South Korean fund Centroid Investment Partners and the American-based Steel Partners. Steel Partners had specifically proposed to acquire a 51 percent controlling interest in the company at a price point of 18 dollars per share. This financial environment forced the board to weigh immediate liquidity against the potential for future organic growth within a highly specialized medical technology niche.

Board Justification for Rejecting Billion Dollar Valuation Proposals

The strategic rationale behind halting the sale centers on the board's belief that the offered prices did not accurately reflect InMode's intrinsic value or long-term potential. While the bid from Steel Partners valued the company at approximately 1.13 billion dollars, the committee ultimately found these terms insufficient to justify a total or partial change in control. According to the company's official statement, the committee concluded that "none of them were satisfactory" for the stakeholders. This decision immediately impacted the company's standing on the public markets, where investors reacted with significant selling pressure, resulting in a market capitalization drop to approximately 900 million dollars.

Categories

Topics

Related Coverage